From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Notable Contracts: Stemnion Award for Cell-Based Wound Therapeutics

by Global Biodefense Staff
May 22, 2013

Amnion-derived Multi-potent Progenitor cellsThe U.S. Navy last month awarded Stemnion, Inc. a contract for continued therapeutic development efforts in support of the Naval Medical Research Center’s cellular combat wound initiative.

The initiative seeks to obtain a novel cellular wound healing technology that will accelerate and improve healing of a variety of combat-related injuries and their associated chronic wounds. NMRC seeks to use Amnion-derived Multi-potent Progenitor cells (AMP cells) and their secreted cytokine solution (ACCS) to decrease loss of tissue, obtain a more rapid wound closure and decrease scarring.

Applications include burn wounds, eye injuries and therapies designed to strengthen suture sites for abdominal surgery patients. It is expected that the benefits of therapies developed to care for wounded military personnel will be immediately applicable to civilian patients across a broad spectrum of needs that range from burn victims to adults afflicted with the slow-healing wounds typical of Type II diabetes. 

The award builds on Stemnion’s successful completion of pre-clinical animal trials and safety testing, including multiple toxicology studies that resulted in FDA permission to proceed with a 2009 Phase I human clinical trial using ACCS to demonstrate safety in the treatment of partial thickness burns.

Those activities funded under the effort include preparation and development of materials for clinical trials; research and development of controlled-release and tissue-specific release formulations; room temperature stabilized formulations; immunology research; and for ocular surface clinical research.

The company received $10.2 million for a base year award, with an estimated total contract value of of $30.7 million if two option periods are exercised. 

Stemnion Inc. is based in of Pittsburg, Pa., and controls over 20 patents pending that are directly related to the AMP cell and ACCS cytokine solution therapies that are entering FDA Phase I and Phase II clinical trials.

Further details are available under Solicitation Number: N6264513WM001.

From Our Partners
Tags: Awards

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC